Consolidated Statement Of Cash Flows

Chiome Bioscience Inc. - Filing #7312329

Concept As at
2024-06-30
2024-01-01 to
2024-06-30
As at
2023-12-31
As at
2023-06-30
2023-01-01 to
2023-06-30
As at
2022-12-31
Consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-562,043,000 JPY
-661,150,000 JPY
Depreciation
586,000 JPY
611,000 JPY
Decrease (increase) in trade receivables
32,500,000 JPY
18,308,000 JPY
Subtotal
-671,113,000 JPY
-589,373,000 JPY
Income taxes paid
-5,010,000 JPY
-5,010,000 JPY
Decrease (increase) in inventories
11,664,000 JPY
11,739,000 JPY
Net cash provided by (used in) operating activities
-677,388,000 JPY
-595,281,000 JPY
Increase (decrease) in trade payables
-14,720,000 JPY
4,197,000 JPY
Other, net
-11,621,000 JPY
8,568,000 JPY
Interest paid
-1,282,000 JPY
-910,000 JPY
Cash flows from investing activities
Proceeds from sale of property, plant and equipment
JPY
82,000 JPY
Net cash provided by (used in) investing activities
JPY
82,000 JPY
Cash flows from financing activities
Proceeds from short-term borrowings
22,600,000 JPY
130,800,000 JPY
Proceeds from issuance of shares
454,390,000 JPY
JPY
Repayments of short-term borrowings
-21,500,000 JPY
-16,500,000 JPY
Net cash provided by (used in) financing activities
455,490,000 JPY
113,359,000 JPY
Other, net
JPY
0 JPY
Net increase (decrease) in cash and cash equivalents
-221,898,000 JPY
-481,839,000 JPY
Cash and cash equivalents
1,103,656,000 JPY
1,325,554,000 JPY
1,245,431,000 JPY
1,727,270,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.